DUPIXENT AFFECTS IL-4 AND IL-13 SIGNALING, IMPACTING TWO OF THE SOURCES THAT MEDIATE
ALLERGIC AND EOSINOPHILIC INFLAMMATION1
Type 2 inflammation plays an important role in the pathogenesis of asthma1-3
IL-4 and IL-13 activate multiple cell types and induce multiple mediators involved in
inflammation—contributing to airflow limitation and increasing the risk of severe
DUPIXENT blocks the IL-4/IL-13 pathway and decreases markers of Type 2 inflammation,
TOTAL AND ALLERGEN-SPECIFIC IgE Up to 70% reduction in total IgE from
EOSINOPHILIC LUNG INFLAMMATION despite the presence of normal or increased
blood eosinophil levels
FeNO (a marker of lung inflammation)
Up to 35% reduction from baseline
The mechanism of dupilumab action in asthma has not been
a Fractional exhaled nitric oxide (FeNO) has not been established as
useful for ruling in or ruling out a diagnosis of asthma; however, FeNO is higher in asthma that is
characterized by Type 2 airway inflammation.6
See how eligible patients can access support for DUPIXENT
Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma:
current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in
asthma. Nat Rev Immunol. 2008;8(3):193-204.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled
asthma. N Engl J Med. 2018;378(26):2486-2496.
Ravensberg AJ, Ricciardolo FLM, van Schadewijk A, et al. Eotaxin-2 and eotaxin-3 expression is associated
with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J
Allergy Clin Immunol. 2005;115(4):779-785.
Global Initiative for Asthma. Definition, description, and diagnosis of asthma. In: Global Strategy for
Asthma Management and Prevention. https://ginasthma.org/. Updated 2018. Accessed February 7, 2019.